Table 2.
The cytotoxicity of BrTet or MNPs-Fe3O4 on PBMCs for 48 hours determined by MTT assay
| Groups | OD (mean ± SD) | RGR (%) | Cytotoxicity gradation |
|---|---|---|---|
| BrTet (μM) | |||
| Control | 1.218 ± 0.154 | – | – |
| 0.25 | 1.247 ± 0.111* | 102.38 | Band 0 |
| 0.5 | 1.261 ± 0.079* | 103.50 | Band 0 |
| 1 | 1.222 ± 0.104* | 100.27 | Band 0 |
| 2 | 1.221 ± 0.195* | 100.22 | Band 0 |
| MNPs-Fe3O4 (V/V) | |||
| Control | 0.763 ± 0.023 | – | – |
| 0.025 | 0.741 ± 0.033** | 97.16 | Band 1 |
| 0.05 | 0.737 ± 0.045** | 96.63 | Band 1 |
| 0.1 | 0.697 ± 0.075** | 91.39 | Band 1 |
| 0.2 | 0.552 ± 0.028** | 72.30 | Band 2 |
Notes:
*
P > 0.05, compared with control group;
**
P > 0.05, compared with control group.
Abbreviations: BrTet, 5-bromotetrandrine; MNPs-Fe3O4, magnetic nanoparticles of Fe3O4; OD, optical density; PBMCs, peripheral blood mononuclear cells; RGR, relative growth rate; SD, standard deviation.